| Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer | 09/16 08:00 | globenewswire.com |
| New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes | 09/10 08:00 | globenewswire.com |
| Lexicon Pharmaceuticals to Participate in Upcoming September Investor Conferences | 09/03 16:00 | globenewswire.com |
| Lexicon (LXRX) Up as FDA Maintains Action Date for Zynquista | 08/22 12:30 | zacks.com |
| Lexicon (LXRX) to Reprioritize Portfolio, Slash Jobs, Stock Up | 08/14 13:35 | zacks.com |
| Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial Portfolio | 08/13 08:30 | globenewswire.com |
| Efficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease Among Three Lexicon-Sponsored Presentations at the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists | 08/07 08:00 | globenewswire.com |
| Lexicon Pharmaceuticals Needs To See Real Revenue Acceleration And Clinical/Regulatory Success | 08/03 06:29 | seekingalpha.com |
| Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2024 Earnings Call Transcript | 08/01 23:00 | seekingalpha.com |
| Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Misses Revenue Estimates | 08/01 18:15 | zacks.com |